Next Level Private LLC Has $2.99 Million Stock Holdings in Bristol-Myers Squibb (NYSE:BMY)

Next Level Private LLC increased its stake in shares of Bristol-Myers Squibb (NYSE:BMY) by 8.2% in the fourth quarter, Holdings Channel.com reports. The firm owned 58,223 shares of the biopharmaceutical company’s stock after buying an additional 4,412 shares during the quarter. Bristol-Myers Squibb comprises approximately 1.7% of Next Level Private LLC’s investment portfolio, making the stock its 17th biggest position. Next Level Private LLC’s holdings in Bristol-Myers Squibb were worth $2,987,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in BMY. State Street Corp increased its position in Bristol-Myers Squibb by 0.9% in the 2nd quarter. State Street Corp now owns 92,570,288 shares of the biopharmaceutical company’s stock valued at $5,919,870,000 after acquiring an additional 858,922 shares during the period. Norges Bank acquired a new position in Bristol-Myers Squibb in the 4th quarter valued at approximately $1,873,696,000. Northern Trust Corp increased its position in Bristol-Myers Squibb by 5.8% in the 3rd quarter. Northern Trust Corp now owns 25,292,711 shares of the biopharmaceutical company’s stock valued at $1,467,989,000 after acquiring an additional 1,394,158 shares during the period. Moneta Group Investment Advisors LLC increased its position in Bristol-Myers Squibb by 114,228.7% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 21,469,785 shares of the biopharmaceutical company’s stock valued at $1,544,751,000 after acquiring an additional 21,451,006 shares during the period. Finally, Invesco Ltd. increased its position in Bristol-Myers Squibb by 8.6% in the 3rd quarter. Invesco Ltd. now owns 15,606,587 shares of the biopharmaceutical company’s stock valued at $905,806,000 after acquiring an additional 1,240,902 shares during the period. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Bristol-Myers Squibb Stock Up 1.3 %

Bristol-Myers Squibb stock opened at $53.25 on Thursday. Bristol-Myers Squibb has a 1-year low of $47.58 and a 1-year high of $71.07. The firm has a market capitalization of $107.92 billion, a price-to-earnings ratio of 13.80, a price-to-earnings-growth ratio of 1.59 and a beta of 0.38. The firm’s fifty day moving average price is $50.73 and its two-hundred day moving average price is $52.43. The company has a current ratio of 1.43, a quick ratio of 1.31 and a debt-to-equity ratio of 1.24.

Bristol-Myers Squibb (NYSE:BMY) last announced its earnings results on Friday, February 2nd. The biopharmaceutical company reported $1.70 EPS for the quarter, beating the consensus estimate of $1.55 by $0.15. The company had revenue of $11.48 billion during the quarter, compared to the consensus estimate of $11.19 billion. Bristol-Myers Squibb had a net margin of 17.83% and a return on equity of 50.95%. The firm’s revenue for the quarter was up .6% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.82 earnings per share. On average, equities research analysts predict that Bristol-Myers Squibb will post 6.61 earnings per share for the current fiscal year.

Bristol-Myers Squibb announced that its Board of Directors has approved a stock buyback plan on Thursday, December 7th that permits the company to repurchase $3.00 billion in shares. This repurchase authorization permits the biopharmaceutical company to buy up to 2.9% of its stock through open market purchases. Stock repurchase plans are usually an indication that the company’s board of directors believes its stock is undervalued.

Bristol-Myers Squibb Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, May 1st. Stockholders of record on Friday, April 5th will be issued a $0.60 dividend. The ex-dividend date is Thursday, April 4th. This represents a $2.40 annualized dividend and a dividend yield of 4.51%. Bristol-Myers Squibb’s dividend payout ratio is currently 62.18%.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the stock. StockNews.com upgraded shares of Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Friday, March 1st. Wells Fargo & Company reduced their price objective on shares of Bristol-Myers Squibb from $58.00 to $51.00 and set an “equal weight” rating on the stock in a research note on Tuesday, February 6th. Redburn Atlantic lowered shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $77.00 to $54.00 in a research note on Tuesday, February 6th. Bank of America lowered shares of Bristol-Myers Squibb from a “buy” rating to a “neutral” rating and reduced their price objective for the company from $68.00 to $60.00 in a research note on Wednesday, January 3rd. Finally, Societe Generale lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Monday, March 11th. One analyst has rated the stock with a sell rating, fifteen have issued a hold rating, three have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Bristol-Myers Squibb presently has an average rating of “Hold” and an average price target of $61.12.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.